glp 1 hims The GLP-1 legal battle is heating up. Novo Nordisk sued & Hers after the telehealth company announced plans to sell a compounded oral GLP-1 pill positioned as a lower-cost alternative to Hims & Hers Stock Spikes.

Research on Eli Lillys orforglipron is ongoing, so efficacy data isnt available yet

Pharmacokinetic DDIs of GLP-1 RAs and a Dual GLP-1/GIP RA Drug-Metabolizing Enzyme-and Transporter-Mediated DDIs GLP-1 RAs and a dual GLP-1/GIP RA are now approved for the treatment of type 2 diabetes and obesity, with patients frequently managing coexisting metabolic diseases that require additional medications.137 Consequently, using multiple medications can result in DDIs, often leading to adverse drug reactions, making it crucial to assess the DDI potential.138 To date, there are limited data on clinically significant metabolic enzyme- or transporter-mediated DDIs involving GLP-1 RAs and a dual GLP-1/GIP RA

While insurers receive rebates to offset some of their costs, the list prices of GLP-1 drugs are about $1,000 per month, and growing demand for these medications could put upward pressure on premiums

The rate of loss increases compared to the first month because you are now at a pharmacologically active dose

The point is not that you should be able to read all the side-effects, but rather impress upon you that all medications have potential side effects, and many have lots of them

For kids under 12, we are probably five to seven years away from any approval process, if the trials even go in that direction. Weighty problems The Centers for Disease Control and Prevention reported last month that 21.1% of youths ages 2 to 19 were obese between August 2021 and August 2023